Oncology Central

High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?


Immunotherapy for the treatment of cancer holds the unique promise of durable, systemic antitumor responses capable of targeting malignant disease throughout the body. Just 8 years after the discovery of IL-2 [1], this promise was first fulfilled in a small clinical trial utilizing systemic high-dose IL-2 (HD IL-2) demonstrating a complete response in a metastatic melanoma patient who was cured of all malignant disease and has remained disease free for more than 29 years [2,3].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.